A Study on Health Seeking Behaviors of Patients of Post-Kala-Azar Dermal Leishmaniasis

Table 3

Clinical characteristics and background history of PKDL patients.

Characteristics ()	Categories	Number	Percentage
Past history of Kala-Azar treatment	Yes	175	87.5
	No	25	12.5
Drug used for KA treatment	Sodium Stibogluconate	141	70.5
	Miltefosine	28	1
	Liposomal amphotericin	2	1
Past history of PKDL	Yes	11	5.5
	No	189	94.5
Drug used for PKDL treatment	Sodium stibogluconate	5	2.5
	Miltefosine	4	2
	Liposomal amphotericin	2	1
Family history of KA	Yes	77	38.5
	No	123	61.5
Types of skin lesion	Hypomelanotic	148	74
	Nodular	11	5.5
	Macular	5	2.5
	Mixed	36	18
Splenomegaly	Yes	14	7
	No	186	93
Hepatomegaly	Yes	2	1
	No	198	99
RK-39 test	Positive	194	97
	Negative	6	3
Skin biopsy for LD body	Yes	75	38.5
	No	65	32.5
	Not done	40	20
Treatment	Miltefosine	146	73
	Ambisome	38	19
	Amphotericin deoxycholate	14	7
	Stibogluconate	2	1